期刊
CANCER RESEARCH AND TREATMENT
卷 50, 期 1, 页码 1-10出版社
KOREAN CANCER ASSOCIATION
DOI: 10.4143/crt.2017.307
关键词
Patient derived xenograft; Preclinical model; Immune deficient mouse; Personalized medicine
类别
资金
- Asan Institute for Life Sciences, Asan Medical Center [2017-571]
- Ministry of Health & Welfare, Republic of Korea [H14C2640]
Establishing an appropriate preclinical model is crucial for translational cancer research. The most common way that has been adopted by far is grafting cancer cell lines, derived from patients. Although this xenograft model is easy to generate, but has several limitations because this cancer model could not represent the unique features of each cancer patient sufficiently. Moreover, accumulating evidences demonstrate cancer is a highly heterogeneous disease so that a tumor is comprised of cancer cells with diverse characteristics. In attempt to avoid these discrepancies between xenograft model and patients' tumor, a patient-derived xenograft (PDX) model has been actively generated and applied. The PDX model can be developed by the implantation of cancerous tissue from a patient's tumor into an immune-deficient mouse directly, thereby it preserves both cell-cell interactions and tumor microenvironment. In addition, the PDX model has shown advantages as a preclinical model in drug screening, biomarker development and co-clinical trial. In this review, we will summarize the methodology and applications of PDX in detail, and cover critical issues for the development of this model for preclinical research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据